Read on to learn more about how long Caplyta takes to help reduce these symptoms and how long the drug stays in your body. It may take about a week for Caplyta to begin working. You may not notice ...

JNJ's $14B acquisition of ITCI bolsters its portfolio with Caplyta, showing strong sales and patent protection until 2033.

Analysts say the decision is a “big blow” to a once-promising class of brain therapies that include’s J&J’s aticaprant and a ...

Johnson & Johnson has added to the opioid kappa blues. Months after Neumora reported a phase 3 flop, J&J has stopped ...

The pharma giant is bringing a depression drug prospect into the fold via the $14 billion acquisition of Intra-Cellular Therapies announced in January. Intra-Cellular’s main asset is Caplyta ...

Once the above transaction is completed, J&J will acquire Intra-Cellular Therapies’ sole marketed drug, Caplyta, which is currently approved for two indications — schizophrenia and bipolar ...

Intra-Cellular Therapies' CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar de ...

The top line beat the Zacks Consensus Estimate of $193 million. Caplyta, the only approved drug in Intra-Cellular’s portfolio, was approved by the FDA in December 2019 for treating schizophrenia ...

Important Safety Information Boxed Warnings: Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. CAPLYTA is not approved for the ...

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. CAPLYTA is not approved for the treatment of patients with dementia-related ...